Insight into the inhibitor discrimination by FLT 3 F691L
Chemical Biology & Drug Design, 2018•Wiley Online Library
Fms‐like tyrosine kinase 3 (FLT 3) belongs to the receptor tyrosine kinase family and
expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in~ 30% of
acute myeloid leukemia cases. FLT 3 kinase domain mutation F691L is one of the common
causes of acquired resistance to the FLT 3 inhibitors including quizartinib. MZH 29 and
crenolanib were previously reported to inhibit FLT 3 F691L. However, crenolanib was
reported for the moderate inhibition. We found that Glu661and Asp829 were the most …
expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in~ 30% of
acute myeloid leukemia cases. FLT 3 kinase domain mutation F691L is one of the common
causes of acquired resistance to the FLT 3 inhibitors including quizartinib. MZH 29 and
crenolanib were previously reported to inhibit FLT 3 F691L. However, crenolanib was
reported for the moderate inhibition. We found that Glu661and Asp829 were the most …
Fms‐like tyrosine kinase 3 (FLT3) belongs to the receptor tyrosine kinase family and expressed in hematopoietic progenitor cells. FLT3 gene mutations are reported in ~30% of acute myeloid leukemia cases. FLT3 kinase domain mutation F691L is one of the common causes of acquired resistance to the FLT3 inhibitors including quizartinib. MZH29 and crenolanib were previously reported to inhibit FLT3 F691L. However, crenolanib was reported for the moderate inhibition. We found that Glu661and Asp829 were the most significant residues to target the FLT3 F691L which contribute most significantly to the binding energy with MZH29 and crenolanib. These interactions were found absent with quizartinib. Further free energy landscape analysis revealed that FLT3 F691L bound to MZH29 and crenolanib was more stable as compared to quizartinib.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果